Fox Chase

The NGS panel found that a previously diagnosed primary lung tumor was actually metastatic breast cancer, leading to a change in the patient's treatment.

NEW YORK (GenomeWeb News) – RayBiotech announced on Tuesday a partnership to provide biomarker discovery and validation services to the Fox Chase Cancer Center.

Last month, genetic analysis and interpretation firm N of One said that it had interpreted sequence data from over 4,000 tumors, including from whole genomes, exomes, and targeted panels.

Following last week's announcement that Thermo Fisher plans to buy Life Technologies for $13.6 billion, Ion Torrent customers are taking a wait-and-see approach, although many are optimistic that the acquisition could be a boon to Ion Torrent development and to the next-gen seque

Fox Chase Cancer Center has contracted genomics interpretation company N-of-One to interpret and curate results from its new targeted sequencing-based test, CancerCode45, creating reports for ordering physicians that link genomic findings with potential targeted therapies.

NEW YORK (GenomeWeb News) – Molecular data interpretation firm N-of-One today announced a deal with Fox Chase Cancer Center to provide interpretation and treatment strategy services for genome sequencing and testing.

The Fox Chase Cancer Center has begun offering targeted sequencing to inform cancer treatment using an adaptation of Life Technologies' Ion Torrent AmpliSeq Cancer Panel via its CLIA-certified laboratory.

The Cancer Genome Institute at Fox Chase is now offering CancerCode-45, a targeted sequencing-based test that runs on the Ion Torrent platform and screens for mutations to 45 cancer-related genes.

This story has been updated to include additional information from a US survey on people's attitudes about cost of genetic testing. Originally published June 4.

NEW YORK (GenomeWeb News) – If genetic tests that predict individual cancer risk are not reimbursed by health insurers, some people who have received referrals for those tests may opt not to take them, according to a new study from Fox Chase Cancer Center.

Pages

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.